Ranbaxy Adds India Plant To Make Generic Lipitor As U.S. Exclusivity Ends
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo’s Ranbaxy Laboratories has begun producing its generic of Pfizer’s Lipitor (atorvastatin) anti-cholesterol drug at a plant in India in addition to a U.S. factory as it faces the end of its six months of generic exclusivity rights.